Bill > A01248

This bill prohibits businesses operating in New York from knowingly selling, offering for sale, or delivering xylazine, a pharmaceutical drug used for sedation, anesthesia, muscle relaxation, and pain relief in animals, to individuals under the age of 21, requiring proof of age through government-issued identification. Furthermore, businesses must verify that any sale of xylazine is intended for institutional, veterinary, or scientific purposes, which can be demonstrated by obtaining a copy of the buyer's active veterinary license or an affidavit confirming their eligibility to purchase. Businesses are required to maintain sales records, proof of age, and proof of intended use for at least five years, and violations can result in civil penalties of up to $3,000 for a first offense and $6,500 for subsequent offenses, with collected funds going to the New York state drug treatment and public education fund.

Budget and Finance, Business and Industry, Housing and Urban Affairs

https://www.nysenate.gov/legislation/bills/2025/A1248